| Endocrine-related osteoporosis is a serious adverse effect caused by endocrine therapy of breast cancer, which needs urgent attention. Endocrine therapy can reduce the tumors in premenopausal and postmenopausal women with breast cancer, and effectively increase the rate of breast-conservation. However, a large number of clinical studies have shown that endocrine treatment of breast cancer could cause secondary osteoporosis. Combining endocrine treatment with bisphosphonate can significantly reduce the incidence of osteoporosis in patients with breast cancer. Further studies found that the pathogenesis of endocrine-related osteoporosis is related to estrogen, estrogen receptors, osteoblasts and osteoclasts, vitamin D and parathyroid hormone (PTH). In view of the side effects of bisphosphonates, the overall syndrome differentiation of traditional Chinese medicine is particularly important. Traditional Chinese medicine is mainly used to replenish kidney and liver, regulate spleen and stomach, promote blood circulation, resolve phlegm, and anti-tumor. It is safe and effective. This article focuses on analyzing osteoporosis caused by endocrine therapy of breast cancer and its pathogenesis in modern medicine, TCM etiology and pathogenesis, and the research progress and development prospects of Chinese medicine in the treatment of endocrine-related osteoporosis in breast cancer. We expect this article will be of help for the in-depth study of the mechanism in preventing and treating endocrine-related osteoporosis in breast cancer using Chinese medicine and the research of new target drugs, with the aim of serving clinical and scientific research better. |